Fmr LLC Syndax Pharmaceuticals Inc Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Fmr LLC holds 36,871 shares of SNDX stock, worth $793,463. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,871

Previous 34,070 8.22%

Holding current value

$793,463

Previous $810,000 6.67%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$18.82 - $23.79 $52,714 - $66,635	2,801 Added 8.22%	36,871 $756,000
Q1 2024 May 13, 2024	SELL	$19.71 - $24.57 $130,598 - $162,800	-6,626 Reduced 16.28%	34,070 $810,000
Q4 2023 Feb 13, 2024	SELL	$11.39 - $21.67 $37,427 - $71,207	-3,286 Reduced 7.47%	40,696 $879,000
Q3 2023 Nov 13, 2023	BUY	$14.52 - $21.77 $32,481 - $48,699	2,237 Added 5.36%	43,982 $638,000
Q2 2023 Aug 11, 2023	BUY	$19.35 - $22.31 $3,947 - $4,551	204 Added 0.49%	41,745 $873,000
Q1 2023 May 11, 2023	BUY	$20.66 - $28.98 $6,549 - $9,186	317 Added 0.77%	41,541 $877,000
Q4 2022 Feb 13, 2023	SELL	$20.64 - $26.24 $2.57 Million - $3.27 Million	-124,649 Reduced 75.15%	41,224 $1.05 Million
Q3 2022 Nov 10, 2022	BUY	$18.51 - $24.79 $744,416 - $996,979	40,217 Added 32.01%	165,873 $3.99 Million
Q2 2022 Aug 12, 2022	SELL	$13.64 - $19.48 $860,506 - $1.23 Million	-63,087 Reduced 33.42%	125,656 $2.42 Million
Q1 2022 May 13, 2022	BUY	$14.84 - $22.15 $20,686 - $30,877	1,394 Added 0.74%	188,743 $3.28 Million
Q4 2021 Feb 14, 2022	BUY	$15.23 - $22.47 $2.85 Million - $4.21 Million	187,349 New	187,349 $4.1 Million

Others Institutions Holding SNDX

# of Institutions

203

Shares Held

87.6M

Call Options Held

268K

Put Options Held

76.8K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $1.22B
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account